TherapeuticsMD Inc (TXMD) Shares Gap Up to $6.36
TherapeuticsMD Inc (NASDAQ:TXMD)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $6.57, but opened at $6.36. TherapeuticsMD shares last traded at $6.31, with a volume of 848,336 shares changing hands.
Several equities analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and set a $33.00 price target on shares of TherapeuticsMD in a report on Monday. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $10.00 price target on shares of TherapeuticsMD in a report on Thursday, August 31st. Deutsche Bank AG set a $10.00 price target on shares of TherapeuticsMD and gave the company a “buy” rating in a report on Tuesday, August 22nd. Stifel Nicolaus reaffirmed a “buy” rating and set a $20.00 price target on shares of TherapeuticsMD in a report on Monday, August 21st. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $15.00 price target on shares of TherapeuticsMD in a report on Friday, August 11th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. TherapeuticsMD presently has a consensus rating of “Buy” and an average target price of $16.14.
The company has a 50-day moving average of $5.75 and a 200-day moving average of $5.55. The company’s market cap is $1.32 billion.
TherapeuticsMD (NASDAQ:TXMD) last announced its earnings results on Thursday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. TherapeuticsMD had a negative return on equity of 77.41% and a negative net margin of 462.94%. The firm had revenue of $4.25 million for the quarter, compared to analyst estimates of $4.91 million. During the same quarter last year, the firm posted ($0.11) EPS. The business’s revenue was down 3.4% on a year-over-year basis. On average, analysts expect that TherapeuticsMD Inc will post ($0.44) EPS for the current fiscal year.
In other TherapeuticsMD news, Director Tommy G. Thompson bought 5,000 shares of the firm’s stock in a transaction dated Wednesday, August 30th. The shares were purchased at an average price of $5.99 per share, for a total transaction of $29,950.00. Following the transaction, the director now directly owns 3,555 shares of the company’s stock, valued at approximately $21,294.45. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Large investors have recently made changes to their positions in the company. Carl Domino Inc purchased a new position in shares of TherapeuticsMD during the 2nd quarter valued at approximately $235,000. Raymond James Financial Services Advisors Inc. lifted its position in shares of TherapeuticsMD by 56.1% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company’s stock valued at $207,000 after buying an additional 10,330 shares in the last quarter. Stifel Financial Corp lifted its position in shares of TherapeuticsMD by 125.4% during the 1st quarter. Stifel Financial Corp now owns 429,362 shares of the company’s stock valued at $3,091,000 after buying an additional 238,885 shares in the last quarter. Oppenheimer & Co. Inc. lifted its position in shares of TherapeuticsMD by 94.5% during the 1st quarter. Oppenheimer & Co. Inc. now owns 41,466 shares of the company’s stock valued at $298,000 after buying an additional 20,148 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of TherapeuticsMD by 2.5% during the 1st quarter. JPMorgan Chase & Co. now owns 13,725,853 shares of the company’s stock valued at $98,827,000 after buying an additional 329,245 shares in the last quarter.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.